SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Modernas leaked and subsequently disclosed Phase 3 melanoma-vaccine results drove a sharp selloff: although the vaccine-plus-Keytruda combination reduced recurrence or death risk versus Keytruda alone, traders said the benefit fell short of expectations built into the stocks run-up. The community is split between calling it a sell-the-news reaction and viewing the data as a meaningful advance, while bears question the valuation and commercial prospects.

TeraWulf, Inc. owns and operates fully integrated environmentally clean bitcoin mining facilities in the United States. It will generate domestically produced bitcoin powered by nuclear, hydro, and solar energy. It operates through the Digital Asset Mining and HPC Leasing segments. The company was founded by Paul B. Prager and Nazar M. Khan on February 8, 2021 and is headquartered in Easton, MD.

TeraWulf Inc

A sharp selloff in WULF and other AI/data-center infrastructure stocks is fueling debate over sector weakness, financing needs, debt and dilution. Bulls view the decline as an oversold pullback, citing WULFs power and HPC hosting strategy and AI demand, while bears question execution and whether upcoming results will support the growth case.

Bloom Energy Corp. engages in the manufacture and installation of a solid oxide fuel-cell based power generation platform. Its product, Bloom Energy Server, converts standard low-pressure natural gas or biogas into electricity through an electrochemical process without combustion. The company was founded by K. R. Sridhar, John Finn, Jim McElroy, Matthias Gottmann, and Dien Nguyen on January 18, 2001, and is headquartered in San Jose, CA.

Bloom Energy Corp - Ordinary Shares - Class A

Bloom Energys strong Q3 results and raised full-year outlook were met with a sharp selloff, with traders pointing to negative cash flow amid heavy investment and a high valuation. Bulls see the spending as growth-related and view the drop as excessive, while skeptics question whether earnings growth can translate into cash amid broader pressure on AI-linked stocks.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVIDIAs decline is drawing attention amid a broader tech and semiconductor selloff, as traders debate whether AI infrastructure spending can be financed and sustained after Jensen Huangs comments about scarce capital. Bulls argue demand for AI compute remains strong and view the drop as a buying opportunity, while bears worry about debt, circular financing and a possible slowdown in AI spending.

iShares Silver Trust - Fractional undivided beneficial interests

iShares Silver Trust

SLV is drawing attention after a sharp silver selloff, with traders focused on persistent selling and a break below a key round-number level. The community is split between buyers treating the drop as an opportunity and bearish traders expecting further losses; explanations range from rate and dollar moves to unverified claims of market manipulation.

Western Digital Corp. engages in the development, manufacture, marketing, and sale of data storage devices and solutions. It operates through the Hard Disk Drives (HDD) segment. The company was founded by Alvin B. Phillips in 1970 and is headquartered in San Jose, CA.

Western Digital Corp.

Western Digitals strong quarterly results and upbeat guidance are drawing attention, but shares sold off despite the report. Traders are debating whether the decline reflects broader weakness in AI and storage stocks and fears of a cyclical earnings peak, while bulls point to persistent AI-driven storage demand and continued pricing strength.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X ETF

Direxion Daily Semiconductor Bull 3X Shares

SOXL is drawing attention after a sharp semiconductor selloff tied to supply-chain concerns raised by Lam Researchs CEO and broader doubts about AI spending and chip demand. Traders are split between calling the leveraged ETF oversold and buying the dip, and expecting further losses as concerns about the AI trade and leverage-related volatility persist.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

USO is drawing attention as escalating Iran- and Houthi-related risks to Middle East oil infrastructure and shipping fuel concerns about supply disruption, lifting crude prices. Traders are divided between bulls focused on geopolitical risk and tighter supply, and bears who see the rally as headline-driven or vulnerable if shipping flows normalize and diplomacy advances.

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Merck & Co Inc

Merck is in focus after detailed Phase 3 results for its Keytruda combination with Modernas personalized melanoma vaccine showed reduced recurrence risk versus Keytruda alone. Traders are split between viewing the data as a meaningful oncology advance and seeing a sell-the-news reaction, with some questioning whether the results met elevated expectations or establish broader commercial potential.

BlackBerry Ltd. engages in the provision of intelligent security software and services. It operates through the following segments: QNX, Secure Communications, and Licensing. The QNX segment includes development of safe and reliable software for embedded systems across technology-driven industries. The Secure Communications segment delivers operational resiliency with a government-grade portfolio of secure, certified solutions for mobile fortification, critical communications and crisis management. The Licensing segment focuses on management and monetization of the firm's global patent portfolio. The company was founded by Michael Lazaridis, James Laurence Balsillie, and Douglas E. Fregin on March 7, 1984 and is headquartered in Waterloo, Canada.

BlackBerry Ltd

BlackBerrys sharp decline is being tied by traders to CEO John Giamatteos disclosed share sales, which some view as a negative signal while others argue they may be routine or tax-related; broader weakness in tech stocks is also cited. That concern contrasts with bullish discussion of QNXs record royalty backlog and Alloy Kore momentum.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

INOVIO Announces Favorable Judgment in Litigation with VGXI, Inc. and GeneOne Life Science

INOVIO Announces Favorable Judgment in Litigation with VGXI, Inc. and GeneOne Life Science INOVIO Announces Favorable Judgment in Litigation with VGXI, Inc. and GeneOne Life SciencePR NewswirePLYMOUTH MEETING, Pa., Oct. 20, 2026 PLYMOUTH MEETING, Pa., Oct. 20, 2026 /PRNewswire/ -- INOVIO...

FDA Decision Watch: What Investors Need To Know About Four Upcoming Drug Rulings

Equity

Investors are set to turn their focus on FDA decisions on experimental treatments for hepatitis B, RRP, sickle cell disease and psoriatic arthritis.


FDA Backs PFE's Tukysa Combo in Front-Line Maintenance Breast Cancer

Pfizer's Tukysa combo regimen wins FDA approval for frontline maintenance breast cancer treatment, extending its use beyond the second-line setting.

PGEN Stock Up More Than 50% in 3 Months: Here's What You Should Know

Precigen is building momentum with Papzimeos sales growth, a European regulatory review and progress across its AdenoVerse pipeline.

PGEN vs. IRWD: Which Biotech Stock Offers Better Growth Potential?

Precigen's Papzimeos and Ironwood's Linzess are driving growth, but competition, pipeline progress and single-product reliance shape each biotech's outlook.

Can PGEN's AdenoVerse Pipeline Create Growth Beyond Papzimeos?

Precigen's Papzimeos is gaining commercial momentum, while its pipeline potential through the AdenoVerse platform could create new growth opportunities.

Precigen Gains 43% in 3 Months: Is It an Indication to Buy the Stock?

PGEN's Papzimeos is driving strong early sales, while European expansion and pipeline progress could shape the stock's growth outlook.

Can Papzimeos Drive Precigen's Growth Through the Rest of 2026?

Papzimeos is fueling Precigen's growth, with sales more than doubling sequentially in Q2 and demand continuing to rise in 2026.

INOVIO to Participate in Upcoming Investor Conferences

INOVIO to Participate in Upcoming Investor Conferences INOVIO to Participate in Upcoming Investor Conferences PR Newswire PLYMOUTH MEETING, Pa., Sept. 1, 2026 PLYMOUTH MEETING, Pa., Sept. 1, 2026 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing...

INOVIO Reports Second Quarter 2026 Financial Results and Recent Business Highlights

INOVIO Reports Second Quarter 2026 Financial Results and Recent Business Highlights INOVIO Reports Second Quarter 2026 Financial Results and Recent Business Highlights PR Newswire PLYMOUTH MEETING, Pa., Aug. 12, 2026 U.S. Food and Drug Administration (FDA) review of Biologics License Application...

Inovio Pharmaceuticals, Inc. engages in the provision of designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with human papillomavirus. Its product pipeline includes VGX-3100, INO-3107, INO-5410, INO-4800, and PENNVAX-GP. The company was founded by David B. Weiner on June 29, 1983 and is headquartered in Plymouth Meeting, PA.

Inovio Pharmaceuticals Inc

Extremely Bullish Sentiment

<ul class="summary-bullets"><li><a class="mention" data-mention="$GSK" data-symbol-id="GSK" href="https://stocktwits.com/symbol/GSK" target="_blank">GSK</a>’s hepatitis B treatment achieved a functional cure in 19% of patients in two late-stage trials.</li><li>Inovio’s therapy reduced the need for repeated surgeries in 81.3% of patients with recurrent respiratory papillomatosis.</li><li>Agios is seeking accelerated approval for Mitapivat for patients aged 16 and older with sickle cell disease.</li></ul>After clearing several new and expanded drug uses last week, most notably ImmunityBio’s (IBRX) Anktiva for an additional form of bladder cancer, all eyes now turn to the U.S. Food and Drug Administration’s (FDA) decisions on drugs to treat hepatitis B, respiratory disease, and sickle cell disease.The momentum continues over the next couple of weeks, with the FDA set to issue decisions on GSK (GSK), Sun Pharmaceutical Industries (SUNPHARMA), Inovio Pharmaceuticals (INO), and Agios Pharmaceuticals (AGIO).<img src="https://news.stocktwits-cdn.com/FDA_Decisions_a4eb0d9031.png" alt="FDA Decisions.png"><h2 class="st-heading-2">FDA’s Verdict On GSK’s Hepatitis B Treatment On Oct. 26</h2>The FDA is likely to announce its decision on GSK’s Bepirovirsen, an experimental treatment for adults with chronic hepatitis B, on October 26. The drug is designed to reduce the production of proteins that allow the virus to multiply and help the immune system control the infection, potentially without the need for continuous treatment.The application is supported by Phase 3 B-Well 1 and B-Well 2 trials, in which 19% of eligible patients receiving Bepirovirsen alongside standard treatment achieved a functional cure, compared with none receiving standard treatment alone. A functional cure means the hepatitis B virus remains suppressed without treatment.Among patients with lower viral activity at the start of the study, the functional cure rate was 26%.The FDA granted the application Priority Review and Breakthrough Therapy designation, as the disease affects about 1.7 million people in the United States, according to GSK.<h2 class="st-heading-2">Inovio’s RRP Therapy In Focus</h2>Investors will then focus on Inovio Pharmaceuticals, whose INO-3107, an experimental treatment for adults with recurrent respiratory papillomatosis (RRP), is expected to receive a regulatory decision on October 30.RRP is a rare disease caused by certain strains of human papillomavirus (HPV), which leads to recurring growths in the respiratory tract. Patients often require repeated surgeries to remove these growths.INO-3107 is designed to help the immune system attack HPV-infected cells. Inovio is seeking an accelerated approval, with the disease reportedly affecting an estimated 14,000 people in the U.S.In a Phase 1/2 study of 32 patients, 81.3% required fewer surgeries in the year following treatment, while 28.1% required no surgeries during or after treatment.<h2 class="st-heading-2">Agios Awaits Decision On Mitapivat</h2>With Mitapivat already approved for certain inherited blood disorders, Agios is now seeking an accelerated approval for patients aged 16 and older with sickle cell disease, which can lead to anemia and potential organ damage. The decision is expected on November 1.The oral drug activates an enzyme called pyruvate kinase, which helps red blood cells produce energy and function more effectively.The Phase 3 Rise Up trial, which involved 207 patients, supports the application. In the study, 40.6% of patients receiving Mitapivat achieved a meaningful increase in hemoglobin levels, compared with 2.9% receiving placebo.Additional analyses also showed that patients receiving Mitapivat were less likely to require blood transfusions.<h2 class="st-heading-2">Sun Pharma Wants To Expand Ilumya’s Use</h2>India-based Sun Pharmaceutical Industries, which recently expanded its U.S. operations with the acquisition of Organon (OGN), is awaiting FDA’s decision on Ilumya, an injectable treatment that is being expanded for the treatment of active psoriatic arthritis.Ilumya works by blocking interleukin-23 (IL-23), a protein involved in inflammation. The drug was first approved in the U.S. in 2018 to treat moderate-to-severe plaque psoriasis.Sun Pharma is seeking approval to expand Ilumya’s use beyond skin symptoms to patients with joint-related disease, with a decision awaited on October 29.<h2 class="st-heading-2">How Have AGIO, INO, GSK And Sun Pharma Performed So Far This Year?</h2>Retail sentiment surrounding AGIO, GSK and INO trended in the ‘bullish’ territory, and ‘neutral’ for Sun Pharma.<img src="https://news.stocktwits-cdn.com/YTD_Biotech_1_f3e6a5a9bc.png" alt="YTD Biotech (1).png">The stocks’ movement so far this year has been mixed, with Agios Pharma gaining 15.2%, while Sun Pharma has risen 1.8%. In contrast, GSK has edged 0.2% lower, while Inovio Pharmaceuticals has plunged 43.4%, the worst performer in this cohort.Also read:<a href="https://stocktwits.com/news-articles/markets/equity/rtx-counter-drone-orders-aerovironment-palantir-defense-ai/cZxjx4bRBtI">&nbsp;Stocktwits Defense Watch: RTX Continues Deal Momentum, Ondas-Palantir Launch AI Firm As AeroVironment Strike Four International Deals</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a medicine pill is seen in a hand dressed in a medical glove with the U.S. FDA logo in the background. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images) 

GSK’s hepatitis B treatment achieved a functional cure in 19% of patients in two late-stage trials.

GSK, INO, AGIO And Sun Pharma Await Key FDA Rulings In October That Could Shape Their Drug Pipelines

Agios Pharmaceuticals Inc

Glaxosmithkline plc - ADR

Sun Pharmaceutical Industries Ltd.

Very bullish

Cautiously bullish

Cautiously bearish

Very bearish

Stocktwits sentiment on $SPY just hit its lowest level of the year. How are you feeling about the market right now?

Stocktwits

 just hit its lowest level of the year. How are you feeling about the market right now?

Current Price	$0.8389
Prev Close	$0.7953
Open	$0.7999
Dividend Yield	0.00%
50-Day Moving Average	$1.18
Beta	0.98
Avg. Volume	2.91M
PE Ratio	-0.71

52-Week High	$2.72
52-Week Low	$0.5632
Market Capitalization	$86.74M
EPS (Annual)	-$1.81
Price to Book	15.80
Revenue Per Employee	$583.42

Feed

News

Sentiment

Earnings

Fundamentals

Info

INO Fundamentals